Arch Biopartners Inc. (ARCH.V)
CAD 1.73
(-0.57%)
CAD 1.73
(-0.57%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.98 Million CAD | 105.63% |
| 2022 | 964.68 Thousand CAD | -75.18% |
| 2021 | 3.88 Million CAD | 5625.22% |
| 2020 | 67.88 Thousand CAD | -27.69% |
| 2019 | 93.87 Thousand CAD | 0.0% |
| 2018 | - CAD | 0.0% |
| 2017 | - CAD | 0.0% |
| 2016 | - CAD | -100.0% |
| 2015 | 37.64 Thousand CAD | -26.37% |
| 2014 | 51.12 Thousand CAD | 35.65% |
| 2013 | 37.68 Thousand CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | -100.0% |
| 2008 | 3.65 Million CAD | 122.63% |
| 2007 | 1.64 Million CAD | 3.01% |
| 2006 | 1.59 Million CAD | -16.41% |
| 2005 | 1.9 Million CAD | -28.77% |
| 2004 | 2.67 Million CAD | -6.38% |
| 2003 | 2.85 Million CAD | 188281.62% |
| 2002 | 1518.00 CAD | -10.97% |
| 2001 | 1705.00 CAD | -99.51% |
| 2000 | 349.44 Thousand CAD | 601.82% |
| 1999 | 49.79 Thousand CAD | -50.21% |
| 1998 | 100 Thousand CAD | 996.85% |
| 1997 | 9117.00 CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 298.14 Thousand CAD | 127.13% |
| 2024 Q3 | - CAD | 0.0% |
| 2024 Q2 | - CAD | -100.0% |
| 2023 Q3 | 116.37 Thousand CAD | -95.4% |
| 2023 FY | 1.98 Million CAD | 105.63% |
| 2023 Q4 | -1.09 Million CAD | -1044.28% |
| 2023 Q2 | 2.53 Million CAD | 482.31% |
| 2023 Q1 | 434.71 Thousand CAD | 173.22% |
| 2022 Q1 | 434.9 Thousand CAD | -76.72% |
| 2022 Q3 | - CAD | -100.0% |
| 2022 FY | 964.68 Thousand CAD | -75.18% |
| 2022 Q4 | -593.7 Thousand CAD | 0.0% |
| 2022 Q2 | 1.12 Million CAD | 158.33% |
| 2021 Q2 | 21.08 Thousand CAD | 0.0% |
| 2021 FY | 3.88 Million CAD | 5625.22% |
| 2021 Q4 | 1.86 Million CAD | -6.44% |
| 2021 Q3 | 1.99 Million CAD | 9371.56% |
| 2021 Q1 | - CAD | 100.0% |
| 2020 Q3 | 29.57 Thousand CAD | 0.0% |
| 2020 Q1 | 26.08 Thousand CAD | -59.47% |
| 2020 FY | 67.88 Thousand CAD | -27.69% |
| 2020 Q4 | -17.33 Thousand CAD | -158.63% |
| 2020 Q2 | 29.57 Thousand CAD | 13.38% |
| 2019 Q4 | 64.34 Thousand CAD | 117.92% |
| 2019 Q3 | 29.52 Thousand CAD | 0.0% |
| 2019 FY | 93.87 Thousand CAD | 0.0% |
| 2019 Q2 | - CAD | 0.0% |
| 2019 Q1 | - CAD | 0.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2018 FY | - CAD | 0.0% |
| 2018 Q4 | - CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2017 Q4 | - CAD | 0.0% |
| 2017 Q3 | - CAD | 0.0% |
| 2017 FY | - CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 FY | - CAD | -100.0% |
| 2016 Q1 | - CAD | -100.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2015 FY | 37.64 Thousand CAD | -26.37% |
| 2015 Q2 | - CAD | -100.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 Q4 | 43.00 CAD | 0.0% |
| 2015 Q1 | 37.59 Thousand CAD | -26.46% |
| 2014 Q1 | - CAD | -100.0% |
| 2014 Q2 | 12 Thousand CAD | 0.0% |
| 2014 Q4 | 51.12 Thousand CAD | 411.25% |
| 2014 FY | 51.12 Thousand CAD | 35.65% |
| 2014 Q3 | 10 Thousand CAD | -16.67% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q4 | 37.68 Thousand CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 FY | 37.68 Thousand CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 FY | - CAD | -100.0% |
| 2009 Q2 | 430.78 Thousand CAD | -18.07% |
| 2009 Q3 | - CAD | -100.0% |
| 2009 Q1 | 525.82 Thousand CAD | -73.77% |
| 2008 Q4 | 2 Million CAD | 143.26% |
| 2008 Q3 | 824.02 Thousand CAD | 173.23% |
| 2008 FY | 3.65 Million CAD | 122.63% |
| 2008 Q2 | 301.58 Thousand CAD | -62.71% |
| 2008 Q1 | 808.85 Thousand CAD | 135.39% |
| 2007 Q2 | 226.51 Thousand CAD | -73.4% |
| 2007 FY | 1.64 Million CAD | 3.01% |
| 2007 Q4 | 343.62 Thousand CAD | 30.56% |
| 2007 Q3 | 263.18 Thousand CAD | 16.19% |
| 2007 Q1 | 851.59 Thousand CAD | 279.43% |
| 2006 FY | 1.59 Million CAD | -16.41% |
| 2006 Q4 | 224.43 Thousand CAD | -44.98% |
| 2006 Q3 | 407.89 Thousand CAD | 270.11% |
| 2006 Q2 | 110.2 Thousand CAD | -56.36% |
| 2006 Q1 | 252.54 Thousand CAD | -75.48% |
| 2005 Q2 | 378.07 Thousand CAD | -69.86% |
| 2005 Q1 | 1.25 Million CAD | 259.14% |
| 2005 FY | 1.9 Million CAD | -28.77% |
| 2005 Q4 | 1.03 Million CAD | 318.15% |
| 2005 Q3 | 246.33 Thousand CAD | -34.84% |
| 2004 FY | 2.67 Million CAD | -6.38% |
| 2004 Q1 | - CAD | 0.0% |
| 2004 Q2 | 349.05 Thousand CAD | 0.0% |
| 2004 Q3 | 724.78 Thousand CAD | 107.64% |
| 2004 Q4 | 349.23 Thousand CAD | -51.82% |
| 2003 Q1 | -5609.00 CAD | 0.0% |
| 2003 FY | 2.85 Million CAD | 188281.62% |
| 2003 Q4 | - CAD | 0.0% |
| 2003 Q3 | - CAD | 0.0% |
| 2003 Q2 | - CAD | 100.0% |
| 2002 FY | 1518.00 CAD | -10.97% |
| 2002 Q3 | 10.78 Thousand CAD | 0.0% |
| 2002 Q4 | - CAD | -100.0% |
| 2002 Q1 | 199.00 CAD | 87.74% |
| 2002 Q2 | - CAD | -100.0% |
| 2001 Q4 | 106.00 CAD | -86.75% |
| 2001 Q3 | 800.00 CAD | 33.33% |
| 2001 Q2 | 600.00 CAD | -96.36% |
| 2001 Q1 | 16.46 Thousand CAD | -71.98% |
| 2001 FY | 1705.00 CAD | -99.51% |
| 2000 Q2 | 196.04 Thousand CAD | 293.73% |
| 2000 FY | 349.44 Thousand CAD | 601.82% |
| 2000 Q1 | 49.79 Thousand CAD | 4979000.0% |
| 2000 Q4 | 58.75 Thousand CAD | -24.85% |
| 2000 Q3 | 78.18 Thousand CAD | -60.12% |
| 1999 Q4 | 1.00 CAD | 0.0% |
| 1999 FY | 49.79 Thousand CAD | -50.21% |
| 1999 Q1 | 99.99 Thousand CAD | 9999800.0% |
| 1999 Q2 | 1.00 CAD | -100.0% |
| 1999 Q3 | 1.00 CAD | 0.0% |
| 1998 FY | 100 Thousand CAD | 996.85% |
| 1998 Q4 | 1.00 CAD | 0.0% |
| 1998 Q2 | 1.00 CAD | 0.0% |
| 1998 Q3 | 1.00 CAD | 0.0% |
| 1997 FY | 9117.00 CAD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Covalon Technologies Ltd. | 26.59 Million CAD | 92.541% |
| Hemostemix Inc. | - CAD | -Infinity% |
| Universal Ibogaine Inc. | 1.07 Million CAD | -85.248% |
| Kane Biotech Inc. | 148.98 Thousand CAD | -1231.483% |
| MedMira Inc. | 432.52 Thousand CAD | -358.615% |
| Marvel Biosciences Corp. | - CAD | -Infinity% |
| NervGen Pharma Corp. | - CAD | -Infinity% |
| XORTX Therapeutics Inc. | - CAD | -Infinity% |